FQ
ACRS icon

First Quadrant’s Aclaris Therapeutics ACRS Stock Holding History

First Quadrant’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,773
Closed -$24K – 566
2020
Q4 		$24K Buy
+3,773
New +$15.9K ﹤0.01% 499

Other funds holding ACRS

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

First Quadrant's ACRS Position: Q1 2021 in Review

First Quadrant sold out of Aclaris Therapeutics (ACRS) in Q1 2021, closing a stake of 3,773 shares — an estimated $24K sold.

First Quadrant first reported a position in ACRS in Q4 2020 and held it in 1 quarter. The position peaked at $24K in Q4 2020. 97 funds tracked by Wall St. Rank hold ACRS as of Q1 2021.

  • First Quadrant reported no remaining Aclaris Therapeutics position as of Q1 2021 after selling out during the quarter.
  • First Quadrant sold 3,773 Aclaris Therapeutics shares in Q1 2021, an estimated $24K.
  • First Quadrant first reported a position in Aclaris Therapeutics in Q4 2020 and held it in 1 quarter.
  • First Quadrant's Aclaris Therapeutics position peaked at $24K in Q4 2020.
  • 97 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2021.

Based on First Quadrant's 13F filing for Q1 2021, filed 27 Apr 2021.